• Mashup Score: 5

    COPD is the most prevalent chronic respiratory disease worldwide and a major cause of disability and death. Acute exacerbations of COPD remain a key feature of the disease in many patients and research assessing interventions to prevent and treat them requires a robust definition with high sensitivity and specificity. To date, no such definition exists, and multiple different definitions are used…

    Tweet Tweets with this article
    • #AECOPD carry high risk for long-term disability and death. As the search for a standardised measure continues, study investigators must ensure definitions are explicit and justified to better understand how to prevent and manage these episodes. https://t.co/vdFhomGpOn

  • Mashup Score: 6

    Pulmonary rehabilitation is an effective treatment for people with a range of chronic lung diseases. In recent years, there have been substantial advances in the science underpinning pulmonary rehabilitation. Advances have been seen in the patient groups in whom it is indicated; in the breadth of programme content; in new methods of delivery; and not least, in important outcomes. This Monograph…

    Tweet Tweets with this article
    • #pulmonaryrehab is a safe invention during or following an #AECOPD that can improved exercise capacity and QoL and reduce the risk of hospital readmissions and mortality @toplungdoc @DrArwelWJones https://t.co/ZqWYj4kNmH https://t.co/gZPNSzE75v

  • Mashup Score: 1

    The main goal of management for COPD is to minimise symptoms and prevent exacerbations [1]. For patients with COPD, exacerbations are a major determinant of reduced quality of life, progressive decline in lung function and increased mortality, particularly from cardiovascular causes [1, 2]. Risk factors predicting future exacerbations include a prior exacerbation, increasing age, worsening lung…

    Tweet Tweets with this article
    • #AECOPD are associated with considerable morbidity and mortality. In a well-designed RCT, Schenk and colleagues show that simvastatin reduces COPD exacerbations by 23% relative to placebo in patients optimised on preventive inhaler therapy. https://t.co/L7xt8gd8A7 https://t.co/hyIGle1vLB

  • Mashup Score: 4

    Background Several studies have shown that statins have beneficial effects in COPD regarding lung function decline, rates and severity of exacerbation, hospitalisation and need for mechanical ventilation. Methods We performed a randomised double-blind placebo-controlled single-centre trial of simvastatin at a daily dose of 40 mg versus placebo in patients with Global Initiative for Chronic…

    Tweet Tweets with this article
    • #AECOPD cause a lot of suffering and healthcare burden. In this study, oral simvastatin 40 mg/day reduced time to first exacerbation and exacerbation frequency in a double-blind, randomised controlled trial. https://t.co/QQdtfhIT6S https://t.co/Ca7NPGe9jT

  • Mashup Score: 0

    Background The generic term “exacerbation” does not reflect the heterogeneity of acute exacerbations of COPD (AECOPD). We utilised a novel algorithmic strategy to profile exacerbation phenotypes based on underlying aetiologies. Methods Patients hospitalised for AECOPD (n=146) were investigated for aetiological contributors summarised in a mnemonic acronym ABCDEFGX (A: airway virus; B: bacterial;…

    Tweet Tweets with this article
    • Hospitalised #AECOPD present as complex multidimensional clinical phenotypes, often comprising multiple distinct aetiologies. Profiling AECOPDs according to their multifactorial aetiological components has important prognostic and therapeutic implications. https://t.co/uBpg7daQ2I https://t.co/hOpOW0RUW4

  • Mashup Score: 2

    Exacerbations of COPD remain a leading cause of emergency hospitalisations worldwide, and up to 28% of patients are readmitted within 30 days of discharge [1]. Recent analyses of more than 2.3 million COPD hospitalisations highlight the dynamic and time-dependent nature of readmission risk, which peaks within the first 72 h of discharge [2, 3]. Effective readmission prevention strategies remain…

    Tweet Tweets with this article
    • Physiological phenotyping using daily home-based assessments reveals early improvement in load–capacity–drive imbalance following #AECOPD and feasibility of home parasternal electromyography measurement, which tracks symptoms, health status and spirometry https://t.co/R4jg0n6P3b https://t.co/AWwbyJ8l3n

  • Mashup Score: 11

    Background COPD patients often have cardiac comorbidities. Cardiac involvement at the time of a COPD exacerbation is associated with a high short-term mortality, but whether this influences long-term outcomes is unknown. We explored whether biomarkers of cardiac dysfunction at the time of a COPD exacerbation predict long-term outcomes. Methods Two prospective cohorts of patients admitted to…

    Tweet Tweets with this article
    • Elevated NT-proBNP at the time of #AECOPD is associated with higher long-term mortality and a greater likelihood of future cardiac admissions, but not future COPD exacerbations https://t.co/c7045lHRSb https://t.co/l5Lo8UgTYG

  • Mashup Score: 0

    Introduction The impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and associated “lockdown” measures on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is unknown. We aimed to evaluate the change in AECOPD treatment frequency during the first 6 weeks of lockdown in the UK compared with 2019 and assess changes in self-reported behaviour and…

    Tweet Tweets with this article
    • The #COVID19 pandemic has changed healthcare provision and access. This study shows a 38% increase in the number of community treated #AECOPD in 2020 compared with 2019, alongside increased anxiety and inhaler adherence with reduced physical activity. https://t.co/N92oqB6IVs https://t.co/DVE8a22kaT